Acute Bacterial Skin & Skin Structure Infection Market Forecasts to 2030 – Global Analysis By Infection Type (Community-Acquired, Hospital-Acquired and Other Infection Types), Diagnostic Type, Treatment, Route of Administration, Distribution Channel, and

Acute Bacterial Skin & Skin Structure Infection Market Forecasts to 2030 – Global Analysis By Infection Type (Community-Acquired, Hospital-Acquired and Other Infection Types), Diagnostic Type, Treatment, Route of Administration, Distribution Channel, and By Geography

According to Stratistics MRC, the Global Acute Bacterial Skin & Skin Structure Infection Market is accounted for $11,708.32 million in 2023 and is expected to reach $25,243.1 million by 2030 growing at a CAGR of 11.6% during the forecast period. Acute Bacterial Skin and Skin Structure Infection (ABSSSI) refers to a range of bacterial infections affecting the skin and underlying tissues, commonly caused by Staphylococcus aureus and Streptococcus pyogenes. These infections manifest with symptoms like redness, warmth, swelling, and pain at the site of infection. ABSSSIs can range from mild cellulitis to more severe conditions like abscesses or wound infections. Prompt diagnosis and treatment are crucial to prevent complications and promote healing in ABSSSI cases.

According to a study published in the International Journal of Antimicrobial Agents in August 2022, almost 10% of all hospital admissions in the United States and around 15% of all infections treated in European hospitals are due to ABSSSIs.

Market Dynamics:

Driver:

Increasing healthcare expenditure

Rising healthcare expenditures foster research and development efforts aimed at developing innovative therapies and diagnostic tools for ABSSSI. With higher healthcare budgets, healthcare systems can afford to implement advanced diagnostic techniques, such as molecular testing and point-of-care testing. Additionally, increased expenditure allows for the development and adoption of novel therapies targeting antibiotic-resistant bacteria, which is propelling this market further.

Restraint:

Inadequate healthcare infrastructure

Limited healthcare facilities and resources can lead to overcrowding in hospitals and clinics, further exacerbating the strain on the healthcare system and decreasing the delivery of quality care. Without proper facilities for wound care, sterile procedures, and antibiotic administration, managing ABSSSI cases becomes more challenging and may increase the risk of complications and treatment failures. Moreover, inadequate healthcare infrastructure can hinder this market further.

Opportunity:

Advancements in diagnostics

Technological innovations have revolutionized the field of infectious disease diagnosis, enabling faster, more accurate, and more efficient identification of causative pathogens. These advancements in diagnostics not only improve patient outcomes by enabling early and accurate diagnosis of ABSSSI but also contribute to antimicrobial stewardship efforts by optimizing antibiotic use and reducing the risk of antibiotic resistance, which gradually boosts this market growth.

Threat:

Limited awareness and diagnosis

A lack of awareness among both healthcare providers and patients about ABSSSI symptoms, risk factors, and appropriate management strategies leads to delays in seeking medical care, misdiagnosis, or inappropriate use of antibiotics. Moreover, limited awareness of ABSSSI among healthcare providers may contribute to diagnostic errors; as a consequence, patients may experience complications, disease progression, and increased healthcare costs, thereby hampering this market expansion.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Acute Bacterial Skin and Skin Structure Infection (ABSSSI) market. During the pandemic, healthcare resources were diverted towards managing COVID-19 patients, leading to delays in non-emergency procedures, elective surgeries, and routine medical visits. Furthermore, the economic repercussions of the pandemic, including job losses, reduced healthcare budgets, and supply chain disruptions, have created financial constraints for patients and healthcare systems, which hindered this market.

The hospital-acquired segment is expected to be the largest during the forecast period

The hospital-acquired segment is estimated to hold the largest share. It refers to infections that patients acquire during their hospital stay or healthcare facility visit. Hospital-acquired ABSSSI often involves a broader spectrum of bacteria compared to community-acquired infections. Additionally, healthcare providers must carefully consider the choice of antibiotics and may resort to broad-spectrum agents or combination therapy to effectively treat these infections, which significantly boosts this segment’s expansion.

The gram staining segment is expected to have the highest CAGR during the forecast period

The gram staining segment is anticipated to have highest CAGR during the forecast period due to the fact that it is a diagnostic technique used to categorize bacteria based on their cell wall composition. Gram staining involves the application of crystal violet and iodine, which differentiates bacteria into two main groups: gram-positive and gram-negative. Moreover, advancements in Gram staining techniques, such as rapid automated systems and point-of-care testing devices, are driving growth within this segment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a diverse healthcare landscape and varying patterns of infection prevalence across countries. The region's robust healthcare infrastructure and emphasis on evidence-based medicine drive demand for innovative treatments and diagnostic solutions for ABSSSI. Furthermore, collaborations between stakeholders drive innovation, clinical research, and the adoption of advanced diagnostic technologies, thereby driving this region's expansion.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to an increased focus on improving diagnostic capabilities, enhancing infection prevention measures, and developing novel therapeutics to address the rising incidence of ABSSSI. This region is home to some of the major players, such as Melinta Therapeutics, Inc., Melinta Therapeutics, Inc., and Pfizer, Inc. Therefore, it presents significant opportunities for companies to innovate, expand their product offerings, contribute to improving patient outcomes, and drive the region's growth.

Key players in the market

Some of the key players in the Acute Bacterial Skin & Skin Structure Infection Market include Paratek Pharmaceuticals, Inc., Merck & Co., Inc., Cumberland Pharmaceuticals Inc., Allergan, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Glenmark Pharmaceuticals Ltd, Endo Pharmaceuticals Inc., Nabriva Therapeutics PLC, Basilea Pharmaceutica Ltd, Melinta Therapeutics, Inc., Menarini Group and Sandoz Inc.

Key Developments:

In January 2024, Glenmark Pharmaceuticals Ltd. announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment.

In December 2023, Pfizer Inc. announced topline data from the Phase 2b clinical trial investigating its oral Glucagon-like peptide-1 receptor agonist candidate, danuglipron, in adults with obesity and without type 2 diabetes.

In September 2023, Glenmark Pharmaceuticals Limited has entered into a definitive agreement with Nirma Limited to divest 75% stake in its subsidiary, Glenmark Life Sciences Limited (""GLS""), for an aggregate consideration, subject to closing adjustments.

Infection Types Covered:
• Community-Acquired
• Hospital-Acquired
• Other Infection Types

Diagnostic Types Covered:
• Clinical Diagnosis
• Gram Staining
• Blood Tests
• Biomarker Assays
• Molecular Diagnostics
• Microbiological Cultures
• Other Diagnostic Types

Treatments Covered:
• Tedizolid
• Delafloxacin
• Daptomycin
• Vancomycin
• Tigecycline
• Ceftaroline fosamil
• Linezolid
• Oritavancin
• Other Treatments

Route of Administration Covered:
• Parenteral
• Topical
• Oral

Distribution Channels Covered:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channels

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances